We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-13.46%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.59B
AUM Growth
-$417M
Cap. Flow
-$178M
Cap. Flow %
-6.89%
Top 10 Hldgs %
30.75%
Holding
151
New
30
Increased
31
Reduced
32
Closed
17

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$42M
2
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$38M
3
AAC
AAC Holdings
AAC
+$37.8M
4
GSK icon
GSK
GSK
+$37.7M
5
RGNX icon
Regenxbio
RGNX
+$34.1M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$132M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$38M
3
INGN icon
Inogen
INGN
+$26.8M
4
AERI
Aerie Pharmaceuticals
AERI
+$25.4M
5
BSX icon
Boston Scientific
BSX
+$24.9M

Sector Composition

Rank Sector Weight
1 Healthcare 68.89%
2 Financials 4.77%
3 Technology 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCRX icon
26
Pacira BioSciences
PCRX
$1.01B
$28.9M 1.12%
702,485
+490,485
+231% +$30M
ELGX
27
DELISTED
Endologix Inc
ELGX
$28.8M 1.11%
234,711
-10,279
-4% -$1.4M
SRRA
28
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$27.7M 1.07%
+33,710
New +$38M
AKTX
29
Akari Therapeutics
AKTX
$19.3M
$27.6M 1.07%
+1,438
New +$17M
ZVRA icon
30
Zevra Therapeutics
ZVRA
$755M
$27.5M 1.06%
88,781
+21,003
+31% +$6.43M
SAGE
31
DELISTED
Sage Therapeutics
SAGE
$27.5M 1.06%
649,064
+344,064
+113% +$21.2M
TVTY
32
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$27.4M 1.06%
2,465,042
– –
ATRS
33
DELISTED
Antares Pharma, Inc.
ATRS
$26.3M 1.02%
15,451,124
-2,938,665
-16% -$5.76M
RAD
34
DELISTED
Rite Aid Corporation
RAD
$25.6M 0.99%
211,140
+116,640
+123% +$19.4M
GHDX
35
DELISTED
Genomic Health, Inc.
GHDX
$23.1M 0.9%
1,093,516
-89,484
-8% -$2.31M
XNCR icon
36
Xencor
XNCR
$1.3B
$21.9M 0.85%
1,787,000
+376,000
+27% +$7.36M
IMPR
37
DELISTED
IMPRIVATA, INC COM
IMPR
$20.5M 0.79%
1,151,140
+192,988
+20% +$3.45M
GI
38
DELISTED
EndoChoice Holdings, Inc.
GI
$20.4M 0.79%
1,797,709
– –
RLYP
39
DELISTED
RELYPSA INC COM
RLYP
$20.4M 0.79%
1,101,000
+876,000
+389% +$24.1M
MNK
40
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$20.3M 0.79%
+317,931
New +$31.5M
ELV icon
41
Elevance Health
ELV
$80.9B
$19.7M 0.76%
140,806
– –
LOXO
42
DELISTED
Loxo Oncology, Inc
LOXO
$19M 0.74%
1,088,225
-361,926
-25% -$7.08M
LKFT
43
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$18M 0.69%
441,085
-201,523
-31% -$11.6M
LRMR icon
44
Larimar Therapeutics
LRMR
$384M
$17.7M 0.68%
46,123
-37,845
-45% -$17.1M
TARA icon
45
Protara Therapeutics
TARA
$230M
$17.6M 0.68%
31,634
– –
DBVT
46
DBV Technologies
DBVT
$870M
$16.4M 0.64%
46,187
+30,161
+188% +$11.9M
ELOS
47
DELISTED
Syneron Medical Ltd
ELOS
$14.9M 0.58%
2,079,013
+105,068
+5% +$1.01M
AERI
48
DELISTED
Aerie Pharmaceuticals
AERI
$14.3M 0.55%
807,875
-1,403,769
-63% -$25.4M
NSTG
49
DELISTED
NanoString Technologies, Inc.
NSTG
$14.1M 0.55%
880,622
-352,074
-29% -$5.52M
PTLA
50
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$14.1M 0.54%
329,837
– –
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2015 Portfolio in Review

As of Q3 2015, Deerfield Management held 151 positions worth $2.59B, down 14% from $3B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Deerfield Management withdrew a net $178M in Q3 2015, closing 17 positions and reducing 32 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $38M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 71% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Global Blood Therapeutics, Inc. worth $37.5M.

  • Deerfield Management's largest Q3 2015 buy was Global Blood Therapeutics, Inc.: 890,620 shares worth $37.5M.
  • Deerfield Management added most to AAC Holdings in Q3 2015, an estimated $37.8M increase.
  • Deerfield Management's biggest Q3 2015 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $132M.
  • Deerfield Management fully exited Spark Therapeutics, Inc. Common Stock in Q3 2015, selling an estimated $38M.
  • Deerfield Management's ten largest holdings make up 31% of its $2.59B portfolio in Q3 2015.
  • Deerfield Management opened 30 new positions and closed 17 in Q3 2015.
  • Deerfield Management's portfolio value fell 14% quarter-over-quarter to $2.59B.

Based on Deerfield Management's 13F filing for Q3 2015, filed 16 Nov 2015.